Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Share-based Compensation (2019 - 2025)

Harmony Biosciences Holdings' Share-based Compensation history spans 7 years, with the latest figure at $10.0 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 0.99% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $44.9 million, up 5.38%, while the annual FY2025 figure was $44.9 million, 5.38% up from the prior year.
  • Share-based Compensation for Q4 2025 was $10.0 million at Harmony Biosciences Holdings, down from $11.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $12.5 million in Q1 2025 and bottomed at $3.3 million in Q1 2021.
  • The 5-year median for Share-based Compensation is $7.9 million (2023), against an average of $8.1 million.
  • The largest annual shift saw Share-based Compensation soared 797.01% in 2021 before it decreased 0.99% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $4.6 million in 2021, then soared by 49.42% to $6.9 million in 2022, then increased by 27.73% to $8.9 million in 2023, then grew by 13.64% to $10.1 million in 2024, then decreased by 0.99% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Share-based Compensation are $10.0 million (Q4 2025), $11.0 million (Q3 2025), and $11.5 million (Q2 2025).